Australian (ASX) Stock Market Forum

COH - Cochlear Limited

maybe not!
does anyone have a good perspective on why this stock seems to be a "darling" of the Brokers and why its value varies so much?? used to be at $50 and now is $135!!! only in a few years and then back down again!!
 
I like this sort of price action. There's a strong monthly and weekly UP trend. Our job is to buy when there's an acceptable RR setup in the daily chart. The chart shows that after a new all time high, price drifted down with the market (XAO). It's worth noticing that this pullback in price was on lower volume. So low, that the volume indicator (TMF) didn't drop at all. Price then bounces off a prior BO level and continues up to another all time high.

It's worth looking for these pull-backs in strong weekly trends that are done on lower volume.

I'm aware that the difficulty with COH is the low daily volume and thin MD.

coh2704.PNG
 
was wondering as well; fall of AUD should logically increase COH?
Same has happen in the last week this year.. Probably due to most of the customers being overseas , mostly in USA. So one sale results in equivalent of 1.2 sales (??) in Aust.
working out exchange rates and company profits is difficult!?! Almost impossible unless you have a Cray!
 
So I am outta here A.T.M., cashed out today. Has been a strange ride. But I am happy with my return. very happy... gee I think I said that last year ... anyway down to zero now.

but if the ever drops 30% I'll be back!.
 
Cochlear, which last month warned its revenue would be hit by the deferral of implant surgeries in China as the nation dealt with the virus outbreak, abandoned its profit FY20 guidance completely.
“The business has been on track to deliver its earnings guidance driven by strong growth in cochlear implant system sales across the developed markets,” chief executive Dig Howitt said. “However, we expect to experience a significant decline in sales in the immediate future.”
 
Cochlear, which last month warned its revenue would be hit by the deferral of implant surgeries in China as the nation dealt with the virus outbreak, abandoned its profit FY20 guidance completely.
May be well worth putting on the watch list, you never know what can happen, in this sort of market.
 
At the start, coh was branded a medical stock and was not hit, now people realise that noone is going to get an implant in the next 6 months..min...
Was it that hard to see?
 
At the start, coh was branded a medical stock and was not hit, now people realise that noone is going to get an implant in the next 6 months..min...
Was it that hard to see?
I just hope I can buy CSL back at $27, same as last time, just after the GFC.:xyxthumbs
From memory, I think COH got to just under $40 at the same time, but I didn't buy any.
 
Cochlear is in a trading halt, set for a capital raising.

This will test the market. Opportunitistic or in need?
 
Day traded today.
In at $177.30
Out $ 187.00
5.2% net profit.
The entry was a bit off.
Happy with the exit.

F.Rock
 
Cochlear must fork out $US280 million in damages and $US75 million in legal fees after exhausting all of its appeal options in a patent infringement case. It announced the US Supreme Court had denied its petition for a review of the US Federal Circuit Court's decision to uphold the damages against it as a result of a lawsuit by the Alfred E. Mann Foundation for Scientific Research and Advanced Bionics.

- factored in.
 
I often get a bit put off when reading trading books and find examples ( many cherry picked ) to demonstrate a system or concept, but it was refreshing to come across COH today and find a wave pattern that behaved as per my thoughts although it could have a abc corrective phase after the completion of the wave 5

As disclosed many times before I am still learning so feel free to jump in and correct me if wrong or missing something in my logic.

Basic Wave Principle (This is my level at the moment ;) )

1609555720076.png


Recent example of waves 1 to 5 followed by retrace

1609554539483.png


So now I am wondering how far down the retrace will go as at the start of the Wave 1 the low was $187.03 and we are not to far from that now ( $189 ) as the theory is that the cycle will start again. ie up 5 down 3.

Looking at the above we probably do not fit the mold but I like the idea of trades that are oversold and rebound once we confirm the pivot point.

- Are we at that point now? maybe not but I think that we are close.
- Will the $187.03 be support ?

Next we have the Weekly chart which is another interesting chart which sort of backs up the above with a possible pivot point in Wave 2 and Dual Look Back is in oversold territory.

So put the 2 together and we might be onto a possible trade opportunity

1609558195119.png


Thoughts ??
 
Cochlear will return $24 million in JobKeeper money and restart paying dividends, after the return of surgeries around the world boosted sales.
 
Ally Selby: And welcome to Livewire Market’s Buy Hold Sell. I’m Ally Selby. And as many of you know, markets have been off to a rough start in 2022, with the S&P/ASX 200 down around 7 per cent.

So, which companies can help you sleep at night and weather the volatility ahead? Glad you asked. Today we’re joined by Bruce Williams from Elston and Simon Conn from IML.

First up we have Cochlear, which is a global leader in implantable hearing devices and a favourite in many long-term investors’ portfolios. Bruce, I might start on you. Is it a buy, hold or sell?

Bruce Williams (BUY): It's a buy for us Ally. We like it. It’s an under-penetrated market. It’s got proven benefits for its recipients. The valuation is what we would consider reasonably high, but given its runway, the quality of what it does, its market position, we think it’s a terrific stock.

Ally Selby: Over to you, Simon. It obviously suffered during lockdowns, with elective surgeries on ice. But in October, Cochlear provided a net profit guidance up 12 per cent to 20 per cent for FY22. So is it a buy, hold or sell?

Simon Conn (SELL): For us, it’s a great business, but it’s trading at a great price. So it’s clearly a sell for us. I think a lot of the good news is already embedded in the price, and I think it fits in that basket of stocks that have benefited artificially from ultra-low interest rates, where investors have attributed a multiple to future earnings. So 40 times, going towards 30 times next year’s earnings, we just think there’s a lot of good news already in the price and so it’s a sell for us.
 
Matthew Kidman: Welcome to Buy Hold Sell, brought to you by Livewire Markets. My name is Matthew Kidman, and today we’re going to wind back the clock and talk about dividends. Yes. Remember that? That’s what we used to search for in companies before growth became the dominant theme.

Now it’s back to dividends. And to talk about that, we’ve got Blake Henricks from Firetrail and Michelle Lopez from abrdn.

Matthew Kidman: Never thought I’d be saying this, Cochlear, one of the great growth stories of Australia, not a bad yield. Buy, hold, or sell?

Michelle Lopez (BUY): It’s a buy. So I agree with you. It’s not often I talk to Cochlear as a dividend stock. It isn’t a high-yielding stock, but what it is, is it’s a growth yield and a growth dividend.

This is a company that is spinning off a lot of cash. They’re unwinding their CapEx programme. They’re at the tail end of that so the free cash flow that they’re spinning off is very high. They’ve got $500 million of net cash on their balance sheet.

So I think there’s further growth in the dividend, but importantly, operationally, they’re just executing well. They’re super consistent in what they do. They’ve got a really clear strategy and invest for the future for growth. So that runway of growth, whether it’s earnings or whether it’s dividends, is very clear. So it’s a buy.

Matthew Kidman: I like that, growth yield. It’s been tough for Cochlear. A couple of years, hospitals closed around the world. Things are opening up. Buy, hold, or sell?

Blake Henricks (HOLD): I think it’s a hold, but I think if you’re buying it for a dividend, I had a look online, and I actually got a three-year term deposit quote from Judo Bank at 1.55 per cent. So that beats Cochlear’s 1.5.

So I think, for a dividend, it’s a sell. But the market’s growing. Their holding share in the US, growing a bit in Europe. It’s fine, but I’m not buying it for dividends.
 


Write your reply...
Top